Works matching Genentech Inc.

Results: 4164

Estimating Hypothetically Negotiated Royalty Rates after Medlmmune, Inc. v. Genentech, Inc., et al.

Published in:

Journal of Legal Economics, 2008, v. 14, n. 3, p. 43

By:

Porter Jr., Stevan D.

Publication type:

Article

DETHRONING LEAR? INCENTIVES TO INNOVATE AFTER MEDIMMUNE.

Published in:

Berkeley Technology Law Journal, 2009, v. 24, n. 2, p. 971

By:

Dreyfuss, Rochelle Cooper;
Pope, Lawrence S.

Publication type:

Article

Cabilly patent finale.

Published in:

Nature Biotechnology, 2008, v. 26, n. 8, p. 846, doi. 10.1038/nbt0808-846b

By:

Waltz, Emily

Publication type:

Article

Recent Supreme Court decisions and licensing power.

Published in:

Nature Biotechnology, 2008, v. 26, n. 2, p. 183, doi. 10.1038/nbt0208-183

By:

Giordano-Coltart, Jennifer;
Calkins, Charles W

Publication type:

Article

AN EXTRAORDINARY DECADE: THE SUPREME COURT TAKES CHARGE OF RESHAPING PATENT LAW.

Published in:

Charleston Law Review, 2010, v. 4, n. 4, p. 887

By:

Srisiri-Sisson, Warunee

Publication type:

Article

The Federal Circuit's Interpretation and Application of the MedImmune Standard for Declaratory Judgment Jurisdiction.

Published in:

Texas Intellectual Property Law Journal, 2011, v. 19, n. 3, p. 331

By:

Nix, Kelsey I.;
Stemplert, Laurie

Publication type:

Article

BURDEN OF PROOF IN MEDTRONIC: THE FEDERAL CIRCUIT'S IDIOSYNCRATIC PATENT JURISPRUDENCE VETOED, AGAIN.

Published in:

Berkeley Technology Law Journal, 2015, v. 30, p. 777

By:

Zaharia, Sorin G.

Publication type:

Article

THE RETURN OF THE KING: RETHINKING LEAR, MEDIMMUNE, AND THE EFFECTS OF LICENSEE ESTOPPEL IN THE CONTEXT OF AIA POST-GRANT PROCEDURES.

Published in:

New York University Annual Survey of American Law, 2015, v. 71, n. 1, p. 81

By:

GREENE, SCOTT G.

Publication type:

Article

DECLARATORY RELIEF AFTER MEDIMMUNE.

Published in:

Lewis & Clark Law Review, 2010, v. 14, n. 2, p. 491

By:

Levine, David I.;
Belle, Charles E.

Publication type:

Article

Supreme Court Says You Can License and Sue.

Published in:

Research Technology Management, 2007, v. 50, n. 2, p. 9

By:

Berkowitz, Leonard

Publication type:

Article

US allows patent dilution.

Published in:

Chemistry & Industry, 2007, n. 2, p. 9

By:

Walker, Patrick

Publication type:

Article

Supreme Court sides with MedImmune.

Published in:

Nature Reviews Drug Discovery, 2007, v. 6, n. 2, p. 104, doi. 10.1038/nrd2249

By:

Harrison, Charlotte;
Owens, Joanna

Publication type:

Article

U.S. Supreme Court Makes It Easier for Patent Licensee to Have Its Cake and Eat It Too.

Published in:

JOM: The Journal of The Minerals, Metals & Materials Society (TMS), 2007, v. 59, n. 4, p. 80, doi. 10.1007/s11837-007-0057-9

By:

Silverman, Arnold B.

Publication type:

Article

EXPANDING STANDING IN PATENT DECLARATORY JUDGMENT ACTIONS TO BETTER AIR PUBLIC POLICY CONSIDERATIONS.

Published in:

New York University Law Review, 2013, v. 88, n. 1, p. 476

By:

WALRATH, NICHOLAS D.

Publication type:

Article

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphomaThe development of the model and the subsequent analyses were supported by a grant from Genentech, Inc. The sponsors of the study had no role in the model design, cost-utility analysis, or interpretation of the results. All investigators had unlimited access to the model and data. No limitations on publication were imposed. The authors made the final decisions on all analyses presented in the article.

Published in:

Cancer (0008543X), 2005, v. 103, n. 8, p. 1644

By:

John C. Hornberger;
Jennie H. Best

Publication type:

Article

Medimmune v. Genentech: A Game-Theoretic Analysis of the Supreme Court's Continued Assault on the Patentee.

Published in:

Marquette Intellectual Property Law Review, 2011, v. 15, n. 2, p. 503

By:

SMITH, NICHOLAS G.

Publication type:

Article

Great company, bad stock.

Published in:

Nature Biotechnology, 2005, v. 23, n. 2, p. 173, doi. 10.1038/nbt0205-173

By:

Jacobs, Tom

Publication type:

Article

Genentech relaunched with independence intact.

Published in:

Nature Biotechnology, 1999, v. 17, n. 7, p. 634, doi. 10.1038/10842

By:

Glaser, Vicki

Publication type:

Article

Intravitreal Ranibizumab Tedavisi Uygulanan Retina Ven Dal Tıkanıklığına Bağlı Maküla Ödemi Olgularında Görme Keskinliğine Etki Eden Prognostik Faktörler.

Published in:

Retina-Vitreus/Journal of Retina-Vitreous, 2014, v. 22, n. 2, p. 103

By:

DEMİREL, Sibel;
ALAY, Cem;
BATIOĞLU, Figen;
ÖZMERT, Emin

Publication type:

Article

How Much Is More Life Worth?

Published in:

2006

By:

Brock, Dan W.

Publication type:

Editorial

Oncogenic BRAF: A new potential therapeutic target.

Published in:: Oncology (08909091), 2011, v. 25, n. 2, p. 112
Publication type:: Article

Announcements.

Published in:: Oncology (08909091), 2009, v. 23, n. 9, p. 743
Publication type:: Article

First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer.

Published in:: Oncology (08909091), 2009, v. 23, n. 2, p. 182
Publication type:: Article

Announcements.

Published in:: Oncology (08909091), 2006, v. 20, n. 14, p. 1877
Publication type:: Article

Trastuzumab and Beyond: New Possibilities for the Treatment of HER2-Positive Breast Cancer.

Published in:

Oncology (08909091), 2006, v. 20, n. 14, p. 1763

By:

Morris, Shannon R.;
Carey, Lisa A.

Publication type:

Article

Fourth Phase III Study Shows Trastuzumab/Chemotherapy Improved Disease-Free Survival in Breast Cancer Patients.

Published in:: Oncology (08909091), 2005, v. 19, n. 11, p. 1
Publication type:: Article

Response of Diabetic Papillopathy to Intravitreal Bevacizumab.

Published in:

2011

By:

Al-Dhibi, Hassan;
Khan, Arif O.

Publication type:

Case Study

Drugs in traffic: the road to approval.

Published in:: Nature Medicine, 2011, v. 17, n. 12, p. 1542, doi. 10.1038/nm1211-1542
Publication type:: Article

Difficult decisions.

Published in:: 2011
Publication type:: Editorial

Companies race to develop first Hedgehog inhibitor cancer drug.

Published in:

Nature Medicine, 2011, v. 17, n. 5, p. 523, doi. 10.1038/nm0511-523

By:

Dolgin, Elie

Publication type:

Article

Fearful of Avastin's fate, Genentech asks for unusual hearing.

Published in:

Nature Medicine, 2011, v. 17, n. 3, p. 233, doi. 10.1038/nm0311-233

By:

Ratner, Mark

Publication type:

Article

MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS.

Published in:

Hematological Oncology, 2023, v. 41, p. 177, doi. 10.1002/hon.3163_112

By:

Roschewski, M.;
Kurtz, D. M.;
Westin, J.;
Lynch, R. C.;
Alig, S. K.;
Macaulay, C.;
Kuffer, C.;
Hogan, G. J.;
Schultz, A.;
Close, S.;
Chabon, J. J.;
Rossi, D.;
Opat, S.;
Hicks, R.;
Hertzberg, M. S.;
Diehn, M.;
Wilson, W.;
Alizadeh, A. A.

Publication type:

Article

News in brief.

Published in:: Chemistry & Industry, 2009, n. 5, p. 7
Publication type:: Article

Lonza expands into biopharm.

Published in:

Chemistry & Industry, 2006, n. 22, p. 10

By:

Eisberg, Neil

Publication type:

Article

Alteplase for the Management of Occluded Central Venous Access Devices: Safety Considerations.

Published in:

Clinical Journal of Oncology Nursing, 2008, v. 12, n. 1, p. 155, doi. 10.1188/08.CJON.155-157

By:

Smith, Lisa Hartkopf

Publication type:

Article

The role of the Data Safety Monitoring Board: why was the Avastin Phase II clinical trial stopped?

Published in:

2006

By:

McLemore MR

Publication type:

Journal Article

The Role of the Data Safety Monitoring Board: Why Was the Avastin Phase III Clinical Trial Stopped?

Published in:

Clinical Journal of Oncology Nursing, 2006, v. 10, n. 2, p. 153, doi. 10.1188/06.CJON.153-154

By:

McLemore, Monica R.

Publication type:

Article

Bevacizumab (Avastin®).

Published in:

Clinical Journal of Oncology Nursing, 2004, v. 8, n. 6, p. 666

By:

Middleton, Gena;
Lapka, Denise V.

Publication type:

Article

Alteplase (Cathflo Activase ).

Published in:

Clinical Journal of Oncology Nursing, 2004, v. 8, n. 4, p. 417, doi. 10.1188/04.CJON.417-418

By:

Middleton, Gena;
Ruzevick, Bette;
Lindemann, Karen

Publication type:

Article

FDA Approves New Agent for Occluded Central Venous Access Devices.

Published in:: Clinical Journal of Oncology Nursing, 2002, v. 6, n. 2, p. 72
Publication type:: Article

ONS Foundation to Fund Outcomes Research and Symptom Management Grants.

Published in:: ONS News, 2001, v. 16, n. 1, p. 6
Publication type:: Article

Drug & therapeutics update.

Published in:: 2013
Publication type:: Product Review

MARKETPLACE: Drug & therapeutics update.

Published in:: Oncology Exchange, 2012, v. 11, n. 3, p. 47
Publication type:: Article

Phase III/IV.

Published in:: Applied Clinical Trials, 2005, v. 14, n. 7, p. 14
Publication type:: Article

LIMITING UNFETTERED CHALLENGES TO PATENT VALIDITY: UPHOLDING NO-CHALLENGE CLAUSES IN PRE-LITIGATION PATENT SETTLEMENTS BETWEEN PREEXISTING PARTIES TO A LICENSE.

Published in:

Cardozo Law Review, 2014, v. 35, n. 4, p. 1649

By:

Roper, Nicholas

Publication type:

Article

CITY OF HOPE V. GENENTECH: KEEPING FIDUCIARY DUTIES WHERE THEY BELONG.

Published in:

Berkeley Technology Law Journal, 2009, v. 24, n. 1, p. 179

By:

McBride, Reed C.

Publication type:

Article

DECLARATORY JUDGMENT ACTIONS IN PATENT CASES: THE FEDERAL CIRCUIT'S RESPONSE TO MEDIMMUNE V. GENENTECH.

Published in:

Berkeley Technology Law Journal, 2008, v. 23, n. 1, p. 161

By:

Saionz, Jennifer R.

Publication type:

Article

Genentech's stance on biodiversity riles staff.

Published in:

Nature, 1992, v. 358, n. 6382, p. 97, doi. 10.1038/358097b0

By:

Lehrman, Sally

Publication type:

Article

Money no object.

Published in:

Nature, 1990, v. 347, n. 6294, p. 605, doi. 10.1038/347605b0

By:

Gershon, D.

Publication type:

Article

Mixed reactions to merger.

Published in:

Nature, 1990, v. 343, n. 6260, p. 681, doi. 10.1038/343681a0

By:

Gershon, D.

Publication type:

Article